![Page 1: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/1.jpg)
1 CHARLOTTETOWN, PEI • CPhA 2013 FINAL PROgRAm
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013conference 2013conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
conference 2013
MOnday,JUnE 3
conference 2013
conference 2013
CPhA 2013
conference 2013conference 2013June 1-4 • Charlottetown, PEIDelta Prince Edward Hotel & Charlottetown Civic Centre
Charlottetown Rocks!
![Page 2: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/2.jpg)
![Page 3: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/3.jpg)
New Oral Anticoagulant Therapy: Is Newer Better? William (Bill) Semchuck, MSc,PharmD,FCSHP Manager, Pharmacy Practice Regina Qu’Appelle Health Region Bill Semchuk is the Manager of Pharmacy Practice in the Regina Qu’Appelle Health Region. His practice, education and research interests revolve around the areas of Cardiovascular Risk Reduction and Thrombosis and the roles that medications play in those areas. Bill received his baccalaureate and masters degrees from the University of Saskatchewan and his doctor of pharmacy degree from Purdue University, West Lafayette, Indiana. He is an Assistant Clinical Professor at the College of Pharmacy and Nutrition as well as the College of Medicine, Univ of Sask. Clinically Bill works in the Lipid Clinic and the Anticoagulation Clinic. He is an active member of numerous professional groups including the Canadian Cardiovascular Pharmacist Network and the Thrombosis Interest Group of Canada. Learning Objectives:
• To discuss the evolution in availability of anticoagulants • To review clinical trial data pertaining to the novel oral anticoagulant agents • To discuss clinical considerations in the use of these agents • To discuss the role of the pharmacist in the management of patients receiving
anticoagulant therapy Description: The therapeutic options to manage patients with and at risk of thrombotic events have changed dramatically over the past 4 years. Clinicians and patients are challenged to choose the best agent to decrease the risk as well as morbidity and mortality associated with thrombosis and its treatment. By reviewing clinical trial data, pharmacokinetic and phamacodynamic information and applying that to patient/client situations, decisions can be made in concert with patient’s input. Pharmacists can play a key role in aiding in appropriate use of these agents
![Page 4: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/4.jpg)
New Oral Anticoagulant Therapy: Is Newer Better?
Wm Semchuk, MSc, PharmD, FCSHP Manager, Pharmacy Practice Regina Qu’Appelle Health Region
![Page 5: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/5.jpg)
Learning Objectives
• To discuss the evolution in availability of anticoagulants
• To review clinical trial data pertaining to the novel oral anticoagulant agents
• To discuss clinical considerations in the use of these agents
• To discuss the role of the pharmacist in the management of patients receiving anticoagulant therapy
![Page 6: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/6.jpg)
Conflict of interest disclosure:
Company Involvement
1. Boehringer Ingelheim - Advisory Board and Honoraria 2. Sanofi Aventis - Advisory Board, Honoraria and
Research Grants 3. BMS - Advisory Board, Honoraria
4. GSK - Honoraria
5. Bayer - Advisory Board, Honoraria
6. Pfizer - Advisory Board, Honoraria
7. Astra Zeneca - Advisory Board, Honoraria
3
![Page 7: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/7.jpg)
Parenteral
Oral
1910 2010 1960 1950 1940 1930 1920 1970 1980 1990 2000
Heparin
Warfarin
LMWH’s
Direct Thrombin Inhibitors
Indirect FXa Inhibitors
Direct Thrombin Inhibitors
Direct FXa Inhibitors
Adapted from: Weitz J, Hirsh J. Chest. 2001;119:95S; Alban. Eur J Clin Invest 2005; Link. Circulation 1959; Maraganore et al. Biochemistry 1990
Timeline of Anticoagulation Options
![Page 8: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/8.jpg)
2008 2011 2010 2009
Dabigatran VTE prophylaxis following THR/TKR
Health Canada Approvals of New Oral Anticoagulants
Rivaroxaban VTE prophylaxis following THR/TKR
Apixaban VTE prophylaxis following THR/TKR
Dabigatran Stroke prevention in AF
Apixaban Stroke prevention in AF
Rivaroxaban Treatment of DVT
2013 2012
Rivaroxaban Stroke prevention in AF
Health Canada NOC database: http://webprod5.hc-sc.gc.ca/noc-ac/index-eng.jsp
![Page 9: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/9.jpg)
6
Why the Excitement and why the rapid uptake: The promise of new oral anticoagulants
Improved compliance
Improved efficacy
and safety
Less impact on patients’ daily
life
Improved quality of life
Less labour-
intensive
Reduced administrative
costs
Reduced potential for food and drug
interactions
Simplified dosing regimen No dietary restrictions Predictable anticoagulation and no need
for routine coagulation monitoring Can be given at fixed doses
1. Raghaven N et al. Drugs Metab Dispos 2009;37:74–81; 2. Shantsila E & Lip GY. Curr Opin Investig Drugs 2008;9:1020–1033; 3. Mueck W et al. Clin Pharmacokinet 2008;47:203–216; 4. Mueck W et al. Thromb Haemost 2008;100:453–461; 5. Mueck W et al. Int J Clin Pharmacol Ther 2007;45:335–344
![Page 10: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/10.jpg)
Anticoagulant Prescription Volume in Canada
![Page 11: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/11.jpg)
Oral Anticoagulants
Rivaroxaban
Apixaban
Xa
IIa
TF/VIIa
X IX
IXa VIIIa
Va
II
Fibrin Fibrinogen
Adapted from Turpie Eur Heart J 2008; 29:155
Dabigatran
Warfarin site of action
![Page 12: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/12.jpg)
New Oral Anticoagulants • Direct Thrombin Inhibitors:
– Dabigatran (Pradax® - now Pradaxa®)
• Direct F Xa Inhibitors: – Rivaroxaban (Xarelto®) – Apixaban (Eliquis®) – More to come…..
![Page 13: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/13.jpg)
New Orals: Approved Indications • Approved for use in Canada (May 2013)
–Prophylaxis for elective hip and knee orthopedic surgery (dabigatran, rivaroxaban and apixaban)
–Atrial fibrillation (dabigatran, rivaroxaban, apixaban)
–Treatment of Deep Vein Thrombosis (non symptomatic PE), Treatment of PE (rivaroxaban)
![Page 14: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/14.jpg)
11
Thromboprophylaxis with Rivaroxaban after THR/TKR: Primary efficacy outcome: composite of any DVT, nonfatal PE, or death from any cause
P<0.001
Inci
denc
e (%
)
Eriksson BI,et al. N Engl J Med. 2008;358(26):2765-75.; Kakkar AK, et al. Lancet. 2008;372 (9632):31-39. Lassen MR, et al. N Engl J Med. 2008;358(26):2776-2786;Turpie A, et al. Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4.
P<0.001
P<0.001
P<0.012
TOTAL HIP REPLACEMENT (THR) TOTAL KNEE REPLACEMENT (TKr)
PE: Pulmonary embolism
![Page 15: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/15.jpg)
12
Thrromboprophylaxis with Rivaroxaban after THR/TKR: Major Bleeding Endpoint
Inci
denc
e (%
)
Eriksson BI,et al. N Engl J Med. 2008;358(26):2765-75.; Kakkar AK, et al. Lancet. 2008;372 (9632):31-39. Lassen MR, et al. N Engl J Med. 2008;358(26):2776-2786; Turpie A, et al. Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4.
P=NS
P=NS
P=NS
P=NS
![Page 16: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/16.jpg)
P=0.0003 for non-inferiority
RE-MODEL RE-MOBILIZE † RE-NOVATE
P=0.017 for non-inferiority
P<0.0001 for non-inferiority
P<0.0001 for non-inferiority
Thromboprophylaxis with Dabigatran following THR/TKR: Primary Efficacy Outcome: Total VTE or All-Cause Mortality
13
(Hip) (Knee)
Dabigatran
Enoxaparin
Eriksson et al. J Thromb Haemost 2007; Ginsberg et al. J Arthroplast. DOI:10.1016/j.arth.2008.01.132; Eriksson et al. Lancet 2007
P=0.02 *
* P-value that the margin of 9.2% as the upper limit of the 95% CI for ARD was exceeded
P=0.0009 *
† Confidence intervals not reported
![Page 17: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/17.jpg)
14 1.Eriksson BI, et al. 2007 Lancet. 2007;370:949-956; 2. Eriksson BI, et al. J Thromb Haemost. 2007;5(11):2178-2185; 3. The RE-MOBILIZE Writing Committee J Arthroplasty. 2009 Jan;24(1):1-9. Epub 2008 Apr 14.
RE-NOVATE (THR) RE-MODEL (TKR)
RE-MOBILIZE (TKR)
P=NS
P=NS
VTE Prophylaxis with Dabigatran after THR/TKR: Major Bleeding Endpoint
P=NS
![Page 18: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/18.jpg)
Apixaban Enoxaparin
Thromboprophylaxis with Apixiban after THR/TKR: Efficacy and Safety
Efficacy: Any VTE / All-Cause Death Safety: Major or CRNM Bleeding
Enox Dose:
Even
ts (%
)
0
5
10
15
20
25
30
Even
ts (%
)
0
1
2
3
4
5
6
7
40 QD
ADVANCE-2 TKR
P=0.09
3.5
4.8
ADVANCE-2 TKR
15.1
24.4
40 QD
P<0.0001
ADVANCE-1 TKR
P=0.03
ADVANCE-1 TKR
2.9
4.3
30 BID
ADVANCE-3 THR
P<0.0001
1.4 3.9
ADVANCE-3 THR
4.8 5.0
P=0.072
P=0.06
8.8 9.0
30 BID Lassen MR. NEJM 2009;361:594. Lassen MR Lancet 2010;375:875 Lassen MR. NEJM 2010;363:26:2487
![Page 19: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/19.jpg)
Current Status • Dabigatran, Rivaroxaban and Apixaban approved
in Canada for the prevention of VTE in patients undergoing elective THR or TKR
– Rivaroxaban approved by CDR Dec 08
– Dabigatran not recommended by CDR Jan 09
– Apixaban approved by CDR June 2012
• In general – this is short term therapy and these will generally be used for approximately 14 days for TKR and 30 days for THR
16
![Page 20: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/20.jpg)
Atrial Fibrillation Major Risk Factor for Stroke
• Independent risk factor for stroke - increases the risk of stroke by 5-fold1,2,3
• Accounts for approximately 15-20% of all strokes nationally1,4
• Risk of stroke in AF patients by age group – 1.5% in 50–59 year olds – 23.5% in 80–89 year olds
• Risk of stroke is the same in AF patients regardless of whether they have paroxysmal or sustained AF
1.Atrial Fibrillation Investigation Group. Arch Intern Med. 1994 2. Wolf PA, et al. Stroke 1991
3. Savelieva I, et al. Ann Med 2007 4. Singer DE, et al. Chest 2008 AF=atrial fibrillation
![Page 21: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/21.jpg)
Warfarin vs Placebo Relative RR vs. placebo 64% (CI 49–74%) Absolute RR primary 2.7%/yr Absolute RR secondary 8.4%/yr Major extracranial bleeding 31 vs. 17 (ARR -0.3%/yr)
100% 50% 0 -50% -100%
Favours Warfarin Favours Placebo or Control
Adjusted-dose warfarin compared with placebo or control
AFASAK I, 1989; 1990
SPAF I, 1991
BAATAF, 1990
CAFA, 1991
SPINAF, 1992
EAFT, 1993
All trials (n=6)
A Study, Year Relative Risk Reduction (95% CI)
Antiplatelet vs. Placebo Relative RR vs. placebo 19% (CI -1–35%) Absolute RR primary 0.8%/yr Absolute RR secondary 2.5%/yr Major extracranial bleeding 16 vs. 15 (ARR -0.2%/yr)
100% 50% 0 -50% -100% Favours Antiplatelet Favours Placebo
or Control
Antiplatelet agents compared with placebo or control
B Study, Year Relative Risk Reduction (95% CI)
AFASAK I, 1989; 1990 SPAF I, 1991 EAFT, 1993 ESPS II, 1997 LASAF, 1997
Daily Alternate day
UK-TIA, 1999 300 mg daily 1200 mg daily
JAST, 2006
Aspirin trials (n=7)
SAFT, 2003 ESPS II, 1997
Dipyridamole Combination
All antiplatelet trials (n=8)
Hart et al. Ann Intern Med 2007;146(12):857
Warfarin vs Antiplatelet Relative RR 37% (CI 23–48%) Absolute RR primary 0.9%/yr Major extracranial bleeding 40 vs. 22 (ARR -0.2%/yr) Intracranial haemorrhage 20 vs. 7 (ARR -0.2%/yr)
100% 50% 0 -50% -100% Favours Warfarin Favours Antiplatelet
Adjusted-dose warfarin compared with antiplatelet agents
AFASAK I, 1989; 1990
C Study, Year Relative Risk Reduction (95% CI)
AFASAK II, 1998 Chinese ATAFS, 2006 EAFT, 1993 PATAF, 1999 SPAF II, 1994
Age ≤75 y Age >75 y
SIFA, 1997
Aspirin trials (n=8)*
ACTIVE-W, 2006 NASPEAF, 2004
All antiplatelet trials (n=11)
Relative Effects of Antithrombotic Therapies on All Stroke From Randomised Trials in AF
18
![Page 22: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/22.jpg)
NOACs in AF
• 3 large trials have been published that have compared these agents to warfarin – RELY – Dabigatran – ROCKET – Rivaroxaban – ARISTOTLE – Apixaban
• Warfarin was very well utilized in these trials (much better than you would expect in clinical practice)
![Page 23: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/23.jpg)
Comparison of NOAC AF Studies Parameter RELY (dabigatran
etexilate) ROCKET (rivaroxaban)
ARISTOTLE (apixaban)
Design Blinded dabigatran but open-label warfarin (NI)
Double-blind, event driven (NI)
Double-blind, event driven (NI)
Comparators Warfarin vs Dabigatran 110 bid Dabigatran 150 bid
Rivaroxaban 20 mg daily (15 mg daily for CrCl 30-49 ml/Min
Apixaban 5 mg bid (2.5 mg bid if > age > 80, wt < 60kg, Creat > 133 umol/L
Primary efficacy outcome
Stroke (I or H) or systemic embolism
Stroke (I or H) or systemic embolism
Stroke (I or H) or systemic embolism
Primary safety outcome
Major bleeding Major + NMCR bleeding
Major bleeding
Connolly NEJM 2009;361:1139; Patel NEJM 2011;365:883; Granger NEJM 2011;365:981
![Page 24: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/24.jpg)
Comparison of NOAC AF Studies
Parameter RELY ROCKET ARISTOTLE
N 18,113 14,264 18,201
CHADS2 score, mean + SD
2.1 + 1.1 3.5 + 1.0 2.1 + 1.1
Warfarin TTR, mean
64% 55% 62.2%
Reduced dose of intervention drug
1.1% 4.7%
![Page 25: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/25.jpg)
Comparison of NOAC AF Studies
Parameter RELY ROCKET ARISTOTLE
Primary efficacy outcome (ITT analysis)
W 1.7%/yr D110 1.5% yr D150 1.1% yr RR: D110-W 0.91 (0.74-1.11) D150 – W 0.66 (0.53 -0.82)
W 2.4%/yr R 2.1%/yr HR: 0.88 (0.74-1.03)
W 1.6%/yr A 1.3%/yr HR: 0.79 (0.66-0.95)
Death ITT W 4.1/yr D110 3.8%/yr D150 3.6%/yr
Safety pop: W 2.2%/yr R 1.9%/yr
ITT W 3.9%/yr A 3.5%/yr
![Page 26: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/26.jpg)
Comparison of NOAC AF Studies
Parameter RELY ROCKET ARISTOTLE
Major Bleeding
W 3.4%/yr D110 2.7%/yr (p=0.003)
D150 3.1%/yr (p=0.31)
W3.4%/yr R3.6%/yr HR: 1.04 (0.90-1.20)
W3.1%/yr A2.1%/yr HR: 0.69 (0.60-0.80)
Intracranial bleeding
W 0.7%/yr D110 0.2%/yr D150 0.3%/yr
W 0.7% R 0.5% HR: 0.67 (0.47-0.93)
W 0.8%/yr A 0.3/yr HR: 0.42 (0.30 -0.58)
![Page 27: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/27.jpg)
Our Current Pharmacologic Options for AF Stroke Reduction
24 Granger. Circ 2012;125:159-164
![Page 28: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/28.jpg)
INR Control: Clinical Trials vs. Clinical Practice
1 Kalra et al. BMJ 2000 2 Matchar et al. Am J Med 2002
3 Bungard et al. Pharmacotherapy 2000
TTR = Time in Therapeutic Range (INR2.0-3.0) INR = International Normalized Ratio
INR control is an ongoing challenge in routine clinical practice
25
66
9
38 44
18
45 37
18 0
10 20 30 40 50 60 70
INR < 2.0 INR 2.0 - 3.0 INR >3.0
% o
f elig
ible
pat
ient
s
rece
ivin
g w
arfa
rin
Clinical Trial Clinical Practice Clinical Practice
1
2
3
![Page 29: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/29.jpg)
The Importance of Effective INR Control
• 3587 patients randomized to warfarin (INR 2-3) in SPORTIF III & V
• Mean follow-up (± SD) of 16.6 ± 6.3 months
White et al. Arch Intern Med 2007
Poor Control TTR<60% N=1190
Moderate Control TTR 60-75%
N=1207
Good Control TTR>75% N=1190
# Risk Factors (%) 1 2 >3
28.5 30.3 41.2
30.1 29.6 40.3
29.1 35.7 35.2
Mortality (%/year) 4.20 1.84 1.69
Stroke / systemic embolism (%/year) 2.10 1.34 1.07
Major bleeding (%/year) 3.85 1.96 1.58
![Page 30: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/30.jpg)
Dabigatran, Rivaroxaban and Apixaban
• Published data available for all three • Dabigatran, Rivaroxaban, Apixaban – Health
Canada Indication for Prevention of Stroke and Systemic Embolism
• All have positive reviews by CDR
27
![Page 31: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/31.jpg)
VTE: Deep Vein Thrombosis and Pulmonary Embolism
PE
Migration Embolus
Thrombosis is the formation or presence of a thrombus that may obstruct blood flow through a vein or artery1
VTE occurs when thrombosis obstructs blood flow through a vein
The term VTE encompasses:
DVT
PE
1. Anderson FA, et al. Center for Outcomes Research, University of Massachusetts Medical Center; 1998 2. Goldhaber SZ. J Am Coll Cardiol 1992;19:246–247 DVT, deep vein thrombosis; PE, pulmonary embolism
As the venous clot grows, it extends along the vein
PE occurs when parts of the clot detach and travel in the blood to block vessels in the lungs
Thrombus
![Page 32: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/32.jpg)
The Risk of Recurrent VTE
• Overall incidence of recurrent VTE at 6 months is 7%, despite anticoagulant therapy – After an initial DVT, ~80% of the recurrences are DVTs2
– After an initial PE, ~60% of the recurrences are PEs2
1. Line B. Semin Nucl Med. 2001;31:90–101 2. Kearon C. Circulation 2003;107:I22–I30
Events occurring subsequent to an acute episode are termed recurrent VTE, and their prevention is termed secondary prevention
Chance of recurrent VTE in first 3 months
47% If proximal DVT inadequately treated1
<2% If adequate anticoagulant response is
achieved1 (2-4% in subsequent 3 months)
![Page 33: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/33.jpg)
NOACs in VTE
• Studied and published approaches: – IV LMWH followed by NOAC (dabigatran) – IV LMWH + VKA vs NOAC started initially
(rivaroxaban) – Standard therapy followed by extension therapy
(active vs placebo) (dabigatran, rivaroxaban and apixaban)
– Currently only rivaroxaban with a Health Canada Indication
![Page 34: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/34.jpg)
Rivaroxaban in the Treatment of VTE: EINSTEIN Trial (DVT & PE Trials)
• Open-label, event-driven, non-inferiority trials
15 mg bid
Confirmed symptomatic
DVT
without symptomatic
PE
N=3,449 Rivaroxaban
Day 1 Day 21
Enoxaparin (1.0 mg/kg) bid for at least 5
days,
plus VKA target INR 2.5 (INR range 2–3)
20 mg od Rivaroxaban
R
30-d
ay o
bser
vatio
n pe
riod
15 mg bid Confirmed
symptomatic PE
with or without
DVT
N=4,833 Rivaroxaban
Day 1 Day 21
Enoxaparin (1.0 mg/kg) bid for at least 5
days,
plus VKA target INR 2.5 (INR range 2–3)
20 mg od Rivaroxaban
R
30-d
ay o
bser
vatio
n pe
riod
Ineligible if LMWH > 48H, >1 warfarin dose, treatment with thrombectomy, IVC filter, lytics, CI to drugs
Exclusions: Another indication for warfarin; CrCL < 30 mL/min; clinically significant hepatic disease; bacterial endocarditis; active bleeding / high bleed risk; SBP>180 mmHg or DBP>110mmHg; lack of birth control, pregnant, breast feeding; strong P-450 3A4 inducers/inhibitors; life expectancy < 3 months
![Page 35: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/35.jpg)
EINSTEIN: Primary efficacy outcome analysis
Rivaroxaban (n=1,731)
Enoxaparin/VKA (n=1,718)
n (%) n (%) First symptomatic recurrent VTE 36 (2.1) 51 (3.0)
Recurrent DVT 14 (0.8) 28 (1.6) Recurrent DVT + PE 1 (<0.1) 0 (0) Non-fatal PE 20 (1.2) 18 (1.0) Fatal PE/unexplained death where PE cannot be ruled out
3 (0.2) 6 (0.3)
p<0.001 for non-inferiority (one-sided)
1.00 0
0.44 1.04 0.68
Hazard ratio
p=0.076 for superiority (two-sided)
2.00
ITT population EINSTEIN Investigators. N Engl J Med 2010 32
![Page 36: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/36.jpg)
EINSTEIN: Principal safety outcome analysis
Rivaroxaban (n=1,718)
Enox/VKA (n=1,711) HR (95% CI)
n (%) n (%) p value First major or clinically relevant non-major bleeding
139 (8.1) 138 (8.1) 0.97 (0.76–1.22) p=0.77
Major bleeding 14 (0.8) 20 (1.2) 0.65 (0.33-1.30)
p=0.21
Contributing to death 1 (<0.1) 5 (0.3)
In a critical site 3 (0.2) 3 (0.2)
Associated with fall in Hb ≥2 g/dL and/or transfusion of ≥2 units 10 (0.6) 12 (0.7)
Clinically relevant non-major bleeding
126 (7.3) 119 (7.0)
EINSTEIN Investigators. N Engl J Med 2010
Safety population 33
![Page 37: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/37.jpg)
VTE Summary
• Data published • Rivaroxaban Health Canada Approved for
DVT without symptomatic PE as well as PE • Rivaroxaban CDR Approved for DVT
without symptomatic PE Aug 2012 • Dabigatran – no Health Canada approval
yet • Apixaban – no Health Canada approval yet
34
![Page 38: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/38.jpg)
Looking at the drugs further:
• Pharmacologic/PK/PD • Clinical Scenarios:
– Renal dysfunction – Bridging – Monitoring – Bleeding
![Page 39: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/39.jpg)
New Oral Agents – key considerations Rivaroxaban Apixaban Dabigatran
Time to Cmax (hrs) 2.5 to 4 3 2.3-2.9
Half-life (hrs) 5.7-9.2 8-14 14-17
Renal clearance 33% (of active drug) (50% of metabolized inactive drug)
25% 80%
Hepatic clearance 33% (of total) 20%
Prodrug No No Yes
Bioavailability 80% 50% 5%
Antidote? No No No
Potential DIs PGP and Cyp3A4 PGP and Cyp3A4 PGP
Safe in pregnancy? No No No
![Page 40: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/40.jpg)
Renal function decreases with age: this may be an issue with agents that are
primarily renally excreted
1.Cook et al. J Thromb Haemost 2007;5:937-41.
Mean creatinine clearance in patients with VTE1
Age group
Cre
atin
ine
clea
ranc
e (m
L/m
in-1
)
Practice Point: Need to assess renal function prior to initiating these agents and continue to monitor through the treatment period
0
20
40
60
80
100
120
<75 years >75 years >80 years >90 years
37
![Page 41: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/41.jpg)
Dabigatran Rivaroxaban Apixaban
CrCl > 80 mL/min 13.8 hr 8.3 hr 12 hr
CrCl 50-79 mL/min
16.6 hr (AUC ↑ 1.5 fold)
8.7 hr (AUC ↑ 44%)
AUC ↑ 16%
CrCl 30-49 mL/min
18.7 hr (AUC ↑ 3.2 fold)
9 hr (AUC ↑ 52%)
AUC ↑ 29%
CrCl < 30 mL/min 27.5 hr (AUC ↑ 6.3 fold)
9.5 hr (AUC ↑ 64%)
AUC ↑ 44%
ESRD (hemodialysis)
34.1 hr
Br J Clin Pharmacol 2010;70(5):703-712, Clin Pharmacokinet 2010;49(4):259-268, Eliquis Product Monograph 2011.
![Page 42: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/42.jpg)
CrCl 30-50 mL/min
• RELY – No dose adjustment – No significant interaction with thrombotic
outcome but trend to bleeding benefit (cw VKA)
• ARISTOTLE – Creatinine of 133 uM was one (of 3, need 2) to get
2.5 mg BID – No significant interaction with outcomes
• ROCKET – CrCl 30-50 ml/min at enrolment got 15 mg daily – No significant interaction with outcomes.
![Page 43: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/43.jpg)
Drug Monitoring?
• Pre Invasive Procedures • Major Bleeding • Check Adherence or ? Adherence (e.g. new
event - VTE, stroke) • Potential Excess Accumulation:
– Renal and/or Hepatic Dysfunction – Drug Interactions (+ renal/hepatic dysfn)
![Page 44: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/44.jpg)
Bleeding and Reversal • There is no known reversal agent • Strategies will be based on mechanistic results, very small
human studies using laboratory assessment as the endpoint, animal models
• Further data required • Strategies
• Red blood cells • Hydration • Treat source of bleeding (surgery, cauterization) • Charcoal if dosed in last 2 hours • Hemodialysis (rarely practical with hemorrhage) • Consult the local specialist ie. transfusion medicine to determine if the
following may be required: – ? Activated PCC (FEIBA) – ? PCC – ? VIIa
41
![Page 45: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/45.jpg)
Post marketing Reports of Bleeding in New Users of Dabigatran and Warfarin from the
Mini-Sentinel Distributed Database, Oct 2010 – Dec 2011
Analysis Dabigatran Warfarin
Pt N # of events
Incidence (no of events /100,000 days at risk)
Pt N # of events
Incidence (no of events /100,000 days at risk)
GI Bleed* 10,5999 16 1.6 43451 160 3.5
ICH* 10587 8 0.8 43594 109 2.4
* Analysis with required diagnosis of AF
N Engl J Med 2013;368(14):1272-1274
![Page 46: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/46.jpg)
What is the pharmacist’s role?
• Ensure the dose and the drug is correct to the indication
• Make sure that “therapeutic drift” is minimized • Assess renal function • Check for Drug Interactions • Educate patients about benefit, risk and what to do • Medic Alert/Pocket Card • Adherence
![Page 47: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/47.jpg)
Population/ Duration
Rivaroxaban Apixaban Dabigatran
VTE Prevention, Orthopedic Surgery (generally 30 days or less)
10 mg daily 2.5 mg BID 220 mg daily
Stroke Prevention, Atrial Fibrillation (lifelong)
20 mg daily or
CrCl 30-50: 15 mg daily
5 mg BID or
2.5 mg BID (unclear HC indications)
150 mg BID or
110 mg BID
VTE Treatment (3 months to lifelong)
For DVT: 15 mg BID then
20 mg daily
Doses/Indications
![Page 48: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/48.jpg)
Absolute Contraindications
• Mechanical valves – excess strokes with dabigatran – rivaroxaban and apixaban – not studied
• Significant valve disease – Excluded from studies
• Liver disease with elevated INR – No experience, can’t monitor
• Pregnancy – All NOACs cross the placenta
• CrCl < 30mL/min (limited experience with apixaban <15 mL/min
![Page 49: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/49.jpg)
Relative Contraindications
• Venous thromboembolism in cancer patients – Small numbers of patients have been studied
• As treatment for Heparin-induced thrombocytopenia – Being studied
• Thrombocytopenia (don’t know cut-offs)
![Page 50: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/50.jpg)
Effect on new oral anticoagulant plasma levels (area (AUC) from drug interactions and recommendations towards new oral anticoagulant dosing
Via Dabigatran Apixaban Edoxaban* Rivaroxaban
Atrovastatin P-gp Competition And CYP3A4
Inhibition
+18% No data yet No effect No effect
Digoxin P-gp Competition
No effect No data yet No effect No effect
Verapamil P-gp competition
+12-180% (reduce dose and take
simultaneously)
No data yet
+53% (SR) (Reduce dose by
50%)
Minor effect (use with caution
if CrCl 15-50 ml/min)
Diltiazem P-pg competition and weak CYP3A4
inhibition
No effect +40% No data yet Minor effect (use with caution if Crcl
15-50 ml/min)
Quinidine P-gp Competition
+50% No data yet +80% (Reduce dose
by 50%)*
+50%
Amiodarone P-gp Competiton
+12-60% No data yet No effect Minor effect (use with caution if Crcl
15-50 ml/min)
Dronedarone P-gp and CYP3A4 inhibitor
+70-100% (US: 2 x 75mg)
No dat yet +85% (Reduce dose by
50%)*
No data yet
Ketoconazole; Itraconazole; Variconazole’ posaconazole
P-gp and BCRP Competition;
CYP3A4 inhibition
+140-150% (US: 2 x 75mg)
+100% No data yet Up to +160%
Red: CI or not recommended, Orange: Reduce dose, Yellow: consider dose reduction Europace 2013;15:625-651
![Page 51: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/51.jpg)
Via Dabigatran Apixaban Edoxaban* Rivaroxaban
Fluconazole Moderate CYP3A4 inhibition
No data yet No data yet No data yet +42% (if systemically administered)
Cyclosporin; tacrolimus P-gp Competition
No data yet No data yet No data yet +50%
Clarithromycin; erythromycin
P-gp Competition and
CYP3A4 inhibition
+15-20% No data yet No data yet +30-54%
HIV protease inhibitors (e.g. ritonavir)
P-gp/BCRP and CYP3A4/CYP2J2
Inducers
No data yet Strong increase
no data yet Up to +153%
Rifampicin; St. John’s wort; carbamazepine;
phenytoin; phenobarbital
P-pg/BCRP and CYP3A4/CYP2J2
Inducers
-66% +54% -35% Up to -50%
Antancids (H2B; PPI; Al-Mg-hydroxide)
GI absorption -12-30% No data yet No effect
No effect
Other factors:
Age ≥ 80 Years Increased plasma level
No data yet
Age ≥ 75 years Increased plasma level
No data yet
Weight ≥ 50 kg Increased plasma level
Renal Function Increased plasma level
Other increased bleeding risk
Pharmacodynamics interactions (antiplatelet drugs; NSAID; systemic steroid therapy; Other anticoagulants); history or active GI bleeding; recent surgery on critical organ (brain; eye); thrombocytopenia (e.g. chemotherapy); HAS-BLED ≥3
Europace 2013;15:625-651 Red: CI or not recommended, Orange: Reduce dose, Yellow: consider dose reduction
![Page 52: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/52.jpg)
Benefit vs Risk
• SPAF – 65-75% reduction in stroke – 2% major bleeds – 10-20% minor bleeds
• DVT – 10 fold or greater reduction in recurrent events – Similar (or slightly lower bleed rates than SPAF)
![Page 53: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/53.jpg)
What to do with bleeds?
• Major: – Blood in urine, stool, vomiting blood – Go to ER
• Minor: – Nosebleeds – Bruising – Cuts – Mention to PCP
• Medic Alert bracelet or pocket card
![Page 54: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/54.jpg)
Adherence
• Education: – What you are on and why – What to expect both good and bad and what to do about it – How long to take
• Educational materials • Adherence Reminders
– “RxmindMe Prescription” App – Provides automatic reminders to patients regarding when to take
medications; tracks number of doses remaining on Rx etc • Compliance Packaging • Discussion at every visit
![Page 55: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/55.jpg)
Caveats with New Drugs
• New agents should not be assumed to be interchangeable with warfarin; each needs to be tested in specific situations –mechanical heart valves –antiphospholipid syndrome –cancer associated thrombosis –acute coronary syndromes –thrombosis in pregnancy
• Only loose guidelines available for perioperative management on these agents
• No antidote exists for any of them
![Page 56: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/56.jpg)
Initiator of anticoagulant treatment:
⁻ Sets indication for anticoagulation; ⁻ Makes choice of anticoagulant; ⁻ Decides on need of proton pump inhibitor; ⁻ Baseline haemoglobin, renal and liver function; ⁻ Provides education; ⁻ Hands out anticoagulation card; ⁻ Organizes follow-up (when, by whom, what?); ⁻ Remains responsible coordinator for follow-up.
First FU: 1 month
Follow-up by primary care giver
-Checks: 1.Compliance (patient should bring remaining pills); 2.Thrombo-embolic events; 3.Bleeding event’ 4.Other side effects; 5.Co-medication and over-the-counter drugs. 6.Need for blood sampling? 1m?
3m 6m?
In case of problems; contacts initiator of treatment.
Else: fills out anticoagulation card an sets date/place for next follow-up.
Europace 2013;15:625-651
![Page 57: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/57.jpg)
Considerations In Use
54
Clinical Evidence
Clinician Judgment
Patient Preference
• Efficacy and Safety data established in discrete populations • Gaps in knowledge • DIs? • Renal dysfunction ? • Special populations?
• Preference and difficulty in utilizing warfarin • Cost/Coverage
• Warfarin stability • Concurrent illness • Drug interactions • Reversibility • Volume of data • Adherence
![Page 58: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/58.jpg)
Summary • The NOACs are becoming essential parts of our therapeutic
arsenal and have entrenched and expanding roles in a number of therapeutic indications: – VTE prophylaxis following orthopedic surgery – SPAF – VTE treatment
• Like any tool, these drugs need to be used wisely and clinicians will need to consider several scenarios prior to prescribing
• Adherence will be essential to ensure best outcomes and is likely best achieved by patient education and monitoring
• Due to the growth of information in this area, vigilance in ensuring the right drug, in the right dose for the right patient is essential 55
![Page 59: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/59.jpg)
“ That’s all very well but does it kill rats?”
CBC Blogger ‘ robughblah’ response to Health Canada approval of dabigatran for stroke prophylaxis in those with atrial fibrillation, Nov
7th 2010
Questions?
56
![Page 60: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/60.jpg)
Canadian Pharmacists Journal session: Translating Research Evidence into Australian Pharmacy Practice: Successes and Challenges
Brief Bio: Ines Krass
Ines Krass is Professor in Pharmacy practice in the Faculty of Pharmacy, the University of Sydney. Over recent years her research has focused on the development and implementation of disease state management programs (DSM) in Australian community pharmacy. She led a national research team which published the first Australian evidence supporting the role of the community pharmacist in caring for patients with diabetes, research which has informed the implementation of current professional services in Australian community pharmacy.
Presentation:
This presentation will give an overview of current professional pharmacy programs funded by the Australian government under the Fifth Community Pharmacy Agreement (5CPA) and trace some of the research which underpinned their development and implementation into practice. It will also highlight barriers and facilitators to service implementation from the perspectives of the pharmacy as an organisation and the stakeholders including pharmacists, general practitioners and consumers.
Learning Objectives:
1. Describe the professional pharmacy services currently offered through Australian Community pharmacies
2. Discuss the supporting evidence for HMR, MedsCheck, Diabetes Medscheck, Asthma and Diabetes DSM
3. Outline facilitators to service implementation
4. Identify important barriers to service implementation
![Page 61: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/61.jpg)
Translating Research Evidence into Australian Pharmacy Practice: Successes and Challenges
Faculty of Pharmacy Professor Ines Krass
![Page 62: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/62.jpg)
Presentation Outline
1. Australian Community pharmacy 2. Investment in research and
development 3. Examples of funded projects and
subsequent implementation 4. Lessons learned 5. 5CPA professional programs
![Page 63: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/63.jpg)
Australian Bureau of Statistics: Population: 23,001,330. Number of Approved Pharmacies (2013): TOTAL 5,325 Approximate average population per pharmacy: 4320
Introduction: Some Key Statistics
![Page 64: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/64.jpg)
Community Pharmacy Statistics
› The sector employed approximately 48,575 people
› The average community pharmacy dispenses 49,738 prescriptions a year
› In 2010, community pharmacies supplied183.9 million Pharmaceutical Benefits Scheme (PBS) scripts worth 7 billion Dollars, up from 2 million scripts in the previous year.
› Community pharmacies contribute an annual turnover of $13 billion
http://www.health.gov.au/internet/annrpt/publishing.nsf/content/strategic-directions-0506-2
![Page 65: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/65.jpg)
Consumer Attitudes to Community Pharmacy
› 90% of Australian customers trust their pharmacist and believe their pharmacy is a quality healthcare destination.
› 82% consider their pharmacist an expert in medicines
› 79% believe pharmacy plays an important role in their healthcare management.
› 66% Australian customers go to their pharmacist before, or instead of, their GP for some minor medical conditions
Pfizer Australia Health Report, 2007 available at http://www.healthreport.com.au/Reports/37.pdf
![Page 66: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/66.jpg)
Government Funding of Professional Programs
› 2001: funding for domiciliary medication reviews (HMR)
› 3rd Guild Government Agreement – 2000-2005 - $400 million for all professional programs (CMI, HMR,RMMR)
› 4th Guild Government Agreement 2006-2010- $566 million - Continuation of HMR and RMMR - New services – asthma, diabetes, DAA
› 5th Guild Government Agreement 2011-2015 - $508 million
![Page 67: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/67.jpg)
Community pharmacy research investment
![Page 68: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/68.jpg)
Principles underpinning R &D
Place of research in the overall health care
environment
Impact of research on the role of the pharmacist
Opportunities to influence policy and practice
Assessment of feasibility in the practice setting
Assessment of barriers and facilitators to uptake
Strategies to address known barriers
![Page 69: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/69.jpg)
Home Medicines Review
A structured and collaborative health care service provided to patients living at home › HMR involves the consumer, their GP,
an accredited pharmacist and regular community pharmacy or other relevant members of the healthcare team
› The accredited pharmacist visits the consumer at their home, reviews their medicine regimen and routine
› Provides their GP with a report. › The GP and consumer then agree on a
medicine management plan. › Home Medicines Review
http://www.medicareaustralia.gov.au/provider/pbs/fifth-agreement/home-medicines-review.jsp
A
strokefoundation.com.au
HMR logo.gif
![Page 70: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/70.jpg)
2CPA -HMR Research Chen et al, J Soc Adm Pharm, 1999; 3/4:134-144
Krass and Smith, Int J Pharm Pract 2000:8:111-120
275 patients 40% rate of change to medication regimen The estimated annual cost savings $222.43 for
implemented changes Gilbert et al, Med J Aust. 2002:177(4):189-92.
1000 patients 3 medication related problems per person Net saving of $120.00 per person
![Page 71: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/71.jpg)
Some potential impacts of HMR
oReduced the number and cost of medications Krass I & Smith C Intl J Pharm Prac 2000; 8:111-120
oImprove medication appropriateness Castelino R et al, Ann Pharmacother. 2010;44: 1922-29.
oImprove drug knowledge and adherence Holland R et al.. Br J Clin Pharmacol 2008 Mar;65(3):303-16
oReduced time to next hospitalisation for warfarin induced bleeding in veterans Roughead EE et al. J Clin Pharm Ther. 2011 Feb;36(1):27-32.
oReduced time to next hospitalisation for heart failure veterans Roughead EE et al. Circ Heart Fail 2009; 2:424-8.
oReduced the number of falls in nursing home patients Zermansky AG Age and Aging 2006 Nov;35(6):586-91
11
Evidence inconclusive?
![Page 72: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/72.jpg)
![Page 73: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/73.jpg)
![Page 74: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/74.jpg)
Chronic Disease Management in Community Pharmacy
1. Diabetes
2. Asthma
Research and Development
http://www.diabeteshealth.com/cartoons/type-2/
![Page 75: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/75.jpg)
Chronology of Diabetes Research in Australia
15
Fourth Community Pharmacy Agreement
Diabetes Pilot Program – DMAS Stage 1
Third Community Pharmacy Agreement Krass et al, Diabetic Medicine 2007; 24:677-
683. I Krass, C Armour, B Mitchell et al.
Diabetes Research and Clinical Practice 2007;75: 3
Second Community Pharmacy Agreement
CL Armour et al. JAPhA 2004, 44:455-466. I Krass, SJ Taylor, C Smith. CL Armour. JAPhA
2005; 45(1): 35-40.
![Page 76: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/76.jpg)
Diabetes care in community pharmacy
› Providing support of self blood glucose monitoring (SBGM),
› Monitoring and promoting patient adherence with medication and other components of self-management
› Identifying and resolving drug related problems
› Providing targeted information and explanations about diabetes and its management
› Motivating patients to take control › Reminding patients of the importance of
regular examinations for the presence of diabetic complications, e.g., eye and feet examinations.
16
The Diabetes Medication Assistance Service
![Page 77: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/77.jpg)
Cycle of monitoring, review and feedback
Patient Behaviour change
Needs assessment
Goal Setting
Possible interventions
Monitoring and feedback
![Page 78: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/78.jpg)
COMMUNITY PHARMACY DISEASE MANAGEMENT SERVICES
53%
72%
61%54%
0%
10%
20%
30%40%
50%
60%
70%
80%
Pre-intervention Post-intervention
Intervention (n=53)Control (n=46)
Final data collection at 9 months
Monthly followups for 9 months
At two weeks 2 nd visitCommence service
Enrol 135 patientsCollect Baseline Data
3 pharmacists in each setting(9 pharmacists)
Training in diabetes
Intervention Group (3 settings)Diabetes Clinic
RuralMetropolitan
Follow up data collection at 9 months
Enrol 135 patientsCollect Baseline Data
14 pharmacistsand a Diabetes Clinic
Control Group (3 settings)Diabetes Clinic
RuralMetropolitan
Program preparationTraining resources
Intervention ProtocolDocumentation
![Page 79: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/79.jpg)
19
![Page 80: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/80.jpg)
Aims
To implement and evaluate a Pharmacy Diabetes Care Program To identify and refer as appropriate people with undiagnosed diabetes; and To support the continuity of care for people with diabetes To improve the health of people with diabetes
![Page 81: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/81.jpg)
H0: There will be no significant difference between intervention and control groups pre- and post intervention in:
• mean HbA1c, blood glucose levels, BP, TC and medication adherence • mean Quality of Life, well being scores • cost per life year /QALY saved
30 Intervention Pharmacies
Diabetes Medication Assistance Service
30 Control Pharmacies
No Service
Adherence assessment
Checks of medication history
Medication review
Meter downloads
Self care information
Checks for long term complications
Lifestyle information
PCDP Study Design
![Page 82: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/82.jpg)
> 400 patients agreed to participate
> 65 ineligible
335 patients enrolled
159 Control Baseline Visit
140 Control Final Visit (6 mos)
18 withdrew 1 death
176 Intervention Baseline Visit
171 Intervention Visit 1 (2 wks)
163 Intervention Visit 2 (1.5 mos)
153 Intervention Visit 3 (3.5 mos)
149 Intervention Final Visit (6 mos)
5 withdrew
8 withdrew
10 withdrew
4 withdrew
Flowchart of DMAS recruitment and completion
Krass et al, Diabetic Medicine 2007; 24:677-683.
![Page 83: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/83.jpg)
Change in HbA1c over time
23
8.08.3
7.9
8.9
7.07.5
8.08.59.0
9.510.0
baseline final
Mean
HbA
1C (%
)
Control (n = 107) Intervention (n = 125)
Intervention Δ HbA1c -1.03% (95%CI -0.8, -1.14)
Control Δ HbA1c -0.27% (95% CI: -0.15, - 0.39)
Krass et al, Diabetic Medicine 2007; 24:677-683.
![Page 84: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/84.jpg)
Economic Outcomes
›Incremental cost over 5 years (discounted) = $3,373
›Cost per incremental life year saved = $24,029.
›PBAC funds interventions well above this amount.
›Likely to be cost effective
![Page 85: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/85.jpg)
Conclusions The DMAS was effective at improving diabetes control as measured by
blood glucose levels and HbA1C.
The service increased patients understanding of long-term management of
their diabetes and improved their adherence to medications.
Both pharmacists and patients identified several benefits of the service and
expressed great satisfaction with the service.
DMAS is likely to be cost-effective when compared with many interventions
that currently funded (e.g. drugs listed on the PBS)
Pharmacy based interventions provide a way of improving health outcomes
and promote more efficient use of existing medicines.
![Page 86: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/86.jpg)
Asthma Management Services
Saini B “Development, Implementation and Evaluation of a Pharmacy Based Asthma Care Model” [PhD Thesis] supervised by Prof C Armour & Ass Prof I Krass
Bosnic-Anticevich S, Saini B, Smith L, Krass I, Armour C “Asthma Self-Management in the Community” [Report] Investigator-initiated grant through 3rd Agreement R&D program
National Implementation: Armour C, Saini B, Bosnic-Anticevich S, Smith L, Krass I, Stewart K, Burton D, Emmerton L “Asthma Pilot Program: Stage 1 Implementation” as part of professional programs and services in the 4th Community Pharmacy Agreement (2005-2010)
2004- 2006
Armour C, Saini B, Bosnic-Anticevich S, Krass I, Taylor S “Innovative Management Scheme: Managing Asthma in Rural Community” [Report] Investigator-initiated grant through 3rd Agreement R&D program
2002- 2003
2004- 2005
Armour C, Saini B, Bosnic-Anticevich S, Krass I, Smith L, Stewart K, Emmerton L, Burton D, Simpson M, Lough S “Pharmacy Asthma Care Program” [Report] Commissioned study through 3rd Agreement R&D program
2008- 2009
2001- 2003
![Page 87: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/87.jpg)
The Asthma DSM Service Six step plan followed
Spirometry at each visit
Medication issues/SEs/asthma control
Inhaler technique
Adherence assessment and Health Beliefs
Identify triggers
Action plan ownership and understanding
Goal setting
![Page 88: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/88.jpg)
PACP recruitment and completion
396 Patients Recruited
Visit 2 166
Control Intervention (PACP)
Baseline Visit 205
19 did not complete
Final Visit 186(90.7%)
Baseline Visit 191
Final Visit 165(86.4%)
15 withdrew
11 more did not complete
Visit 3 44
Optional
![Page 89: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/89.jpg)
Asthma severity (control) status Comparison of control and intervention groups
**
**
**
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Baseline Final Baseline Final
Per
cent
age
Mild
Moderate
Severe
CONTROL INTERVENTION
Armour et al., Thorax 2007 62: 496-502.
![Page 90: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/90.jpg)
Economic Outcome
› Incremental cost over 5 years (discounted) = $590
›Cost per QALY = $2,946 ›PBAC funds interventions well above this amount.
›Cost effective
Gordois et al, Disease Management and Health Outcomes , 2007;15:387-96.
![Page 91: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/91.jpg)
Question?
Can the DMAS or PACP, programs which
has been shown to have clinical and cost effectiveness in a small sample of
pharmacies be effectively translated into broader community practice?
31
![Page 92: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/92.jpg)
Diabetes Pilot Program
Stage 1 DMAS Implementation Trial was to test: - Implementation feasibility - The effectiveness of a 6 month DMAS service versus a 12 DMAS month service
- The sustainability of improvements after the service has been completed
Stage 2 – DMAS implementation in 800 community pharmacies across Australia
32
![Page 93: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/93.jpg)
33
![Page 94: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/94.jpg)
Patient Recruitment
For a patient to be involved in Stage 1 DMAS as part of the Pilot Program, they must:
› have established type 2 diabetes with HbA1c > 7.0% confirmed by test results (within the previous 6 months) from the patient’s GP
› be a regular prescription customer of the pharmacy for at least the previous 3 months in order to generate a meaningful medication history
During Stage 1 - limit of 10 eligible patients per pharmacy
to receive a subsidised DMAS.
34
![Page 95: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/95.jpg)
Training
›Module 1 (pre-reading) of the training manual (an electronic version) sent 2-3 weeks before training workshop
›The workshops comprised a mix of lectures, skills sessions, case discussions and role plays
›Each 2 day training workshop attended by 7-14 pharmacists
35
![Page 96: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/96.jpg)
Credentialing
› Administered by AACP › 3 components:
1. MCQ test based on manual material (end of DAY 1) 2. Assessment of skills in demonstrating the blood
glucose monitor and using the Precision Link software.
3. Case studies on interpretation of blood glucose data (end of DAY 2)
36
![Page 97: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/97.jpg)
Monitoring the implementation process
› Pharmacists - telephone surveys
- focus groups
› Pharmacy Audits › Patients
- telephone surveys
› GPs - telephone surveys
Overall experience –barriers and facilitators
Feedback from customers
Interaction with GPs and Diabetes educators
Impact on business and relationships
Involvement in future DMAS delivery
Overall experience of DMAS
Benefits
Satisfaction with service delivery
Demand/Willingness to pay
Awareness/experience of DMAS
Perceptions of impacts
Communication with pharmacists
Need for DMAS
Compliance with eligibility criteria
Program protocols
![Page 98: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/98.jpg)
Study Design
38
Group 1 6 months
Visit 0 Baseline
Data
Visits 1,2 4 months,
6 month final visit Data
12 months Data
18 months Follow up
data
Group 2 12 months
Visit 0 Baseline
Data
Visits 1,2 4 months,
6 months visit Data
9 months visit
12 months visit Data
18 months Follow up
data
BGL
HbA1c, BP,
Lipids QoL
HbA1c BP
Lipids eGFR QoL
BGL
HbA1c, BP,
Lipids QoL
HbA1c BP
Lipids eGFR QoL
Consumer satisfaction
Consumer satisfaction
![Page 99: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/99.jpg)
RESULTS
DPP Stage 1 Implementation
Results
![Page 100: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/100.jpg)
Key Barriers to DMAS Implementation
Resistance from local GPs and diabetes educators
Insufficient numbers of eligible patients
Lack of staff to facilitate organisation of appointments
Patients not keeping appointments
Shortage of pharmacists to allow for uninterrupted DMAS
Excessive time taken to deliver service
Insufficient pharmacist remuneration for the DMAS
Over commitment of pharmacy to multiple professional
services
![Page 101: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/101.jpg)
Flowchart of DMAS recruitment and completion
41
998 patients agreed to participate
474 INELIGIBLE
524 patients enrolled
260 Group 1
Visit 0
264 Group 2
Visit 0
254 Group 1
Visit 1
249 Group 2
Visit 1
237 Group 2
Visit 2 232 Group 2
Visit 3
220 Group 2
Visit 4
202 Group 2
Visit 5
241 Group 1
Visit 2 221 Group 1
Visit 3
15 withdrew
12 withdrew
5 withdrew
12 withdrew
18 withdrew
18 withdrew
6 withdrew
13 withdrew
19 withdrew
19 withdrew
184 Group 2
Visit 6
203 Group 1
Visit 4
![Page 102: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/102.jpg)
Changes in BGL (mmol/L) during DMAS
42
![Page 103: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/103.jpg)
Proportion of patients at clinical targets for optimum diabetes management
43
Group 1 Group 2
![Page 104: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/104.jpg)
Sustainability: HbA1c by group by time
44
![Page 105: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/105.jpg)
EQ 5D – Changes in Utility Scores
45
0.5
0.55
0.6
0.65
0.7
0.75
0.8
0.85
Baseline: EQ-5D score Completion: EQ-5D score 18 month: EQ-5D score
EQ-5
D s
core
Time Points
Group 1 (n=117)
Group 2 (n=104)
![Page 106: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/106.jpg)
› Increase in their knowledge of diabetes
and its complications
› Pharmacist gave them education on lifestyle issues which resulted in improvements in lifestyle and quality of life
› Patients reported improvements in their understanding of diabetes medications
› Patients thought the most useful part of DMAS was the printouts of their blood glucose results
› Patients reported that the DMAS led to improved monitoring of their diabetes
46
“I have learnt about diet and exercise and to keep going at it. I have seen the benefits already” (Patient 19, TAS)
“Diabetes can damage your eyes and heart....all those things” (Patient 14, WA)
“Having it explained on the printouts was great. Even the doctor was impressed” (Patient 11, VIC)
“I learnt a lot about my medications…. as was having side effects” (Patient 12, WA)
“ It gave the opportunity for closer monitoring of my diabetes and more focus on lifestyle such as increased exercise ” (Patient 22, NSW)
![Page 107: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/107.jpg)
Conclusion
The DMAS may be successfully implemented into diverse community pharmacy settings providing 1. the pharmacy has adequate staff, remuneration and
infrastructure to support service provision; 2. there are good pharmacist-GP relationships; 3. the pharmacy has a pool of eligible patients; and 4. there is effective promotion and integration of the DMAS
within the healthcare sector.
47
FEASIBILITY
![Page 108: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/108.jpg)
Conclusion
› The DMAS resulted in significant health benefits for people with Type 2 diabetes. - Significant improvements in glycaemic control - Reduction in other CVD risk factors - The clinical effectiveness of DMAS was independent of the duration (6
month vs.12 month DMAS) or intensity (5 visits vs. 7 visits) of the service - Based on evidence from large clinical trials 1-3, the extent of improvement in
diabetes control achieved by the DMAS will translate into future cost savings to the health care system in delaying and reducing diabetes related complications.
1. UK Prospective Diabetes Study (UKPDS) Group). Lancet. 1998, 352: 837–853
2. Diabetes Control and Complications Trial Research Group. New England Journal of Medicine. 1993, 329: 977–986
3. Stratton I.M., Adler A.I., Neil H.W. et al. British Medical Journal, 2000; 321: 405-412
48
HEALTH OUTCOMES
![Page 109: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/109.jpg)
Conclusion
› Overwhelmingly, the DMAS service was well received and highly valued by patients
› The most useful aspect of the DMAS was the pharmacists’ support of blood glucose monitoring as a tool to help the patient to effectively self-manage aspects of their diabetes.
› The visit to the pharmacist was worth about the same as a visit to the GP
› Their willingness to pay was based on whether they were currently bulk-billed and the gap they paid over and above the Medicare rebate.
49
![Page 110: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/110.jpg)
DPP Stage 2
› DMAS was rolled out to 800 pharmacies around Australia
› The number of active pharmacists (with 1 or more patients) in the program was 251. This represented 32% of the 785 pharmacists trained and credentialed.
› Only 11% of the potential pool of 5,495 participants (785 pharmacists with 7 patients in the evaluation sample).
› An average of 2.4 patients for every active pharmacist (n=251) in the program.
› A total of approximately 1,000-1,250 patients participated in the DMAS 2 nationally
The program evaluation highlighted several significant barriers to broad implementation.
50
![Page 111: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/111.jpg)
PHARMACY ASTHMA MANAGEMENT SERVICE (PAMS)
• Evidence from RCT • Cost Effective • Implementation trial (Broad Scale) • Sustainability • 3 versus 4 visits over 6 months • Barriers and Facilitators • Business Model • 3 states and 1 territory • WHY IS THIS IMPORTANT ? NOT RCT
PARTICIPANTS
![Page 112: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/112.jpg)
PAMS Baseline vs Final › Asthma Control
0
10
20
30
40
50
60
70
80
90
100
3 visit Baseline 3 visit Final Visit
4 visit Baseline 4 visit Final Visit
Prop
ortio
n of
pat
ient
s (%
)
Time points
Poor
Fair
Good
![Page 113: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/113.jpg)
Key Findings of PAMS implementation trial
› 3 visits over 6 months produced similar clinical and humanistic outcomes to 4 visits
› Visits spaced at baseline, one month later and 6 months › Improvements sustained at 6 months and (inhaler technique)
at 12 months also. › Patients and practitioners liked the service (liked the
spirometry) › Suggest a 3 visit service followed up by 12 month review with
occasional checking for some patients at 6 months would be sufficient to improve and maintain asthma control in most individuals.
![Page 114: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/114.jpg)
DOCUMENT
China National Essential Drug Administration, Policy and Practices Program, Sydney December 2011
Int J Clin Pharm (2012) 34:43–52
![Page 115: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/115.jpg)
Validation of the DOCUMENT
12 week trial 185 community pharmacies 2,1023,923 prescriptions 5,948 DRPs CI rate 0.3% 1.6 IV per prescription Recommendations
- change in therapy (40.1%) - provision of information (34.7%).
› Clinical significance - 13.9% - high - 32% - moderate
Williams M et al Int J Clin Pharm (2012) 34:43–52
![Page 116: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/116.jpg)
Professional Programs in the 5CPA
Pharmacy Practice Incentives (PPI) - $344M
Medication Management
Medicines Use Reviews (Medscheck) - $29.6M
Diabetes Medication Management Service (Diabetes Medscheck) - $12.2M
Home Medicines Reviews (HMR) - $52.11M
Residential Medication Management Reviews (RMMR) - $70M
April 2013
![Page 117: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/117.jpg)
Uptake of MedsCheck/Diabetes MedsCheck
›3,232 pharmacies participating in our GuildCare 5CPA programs
›1 July 2011 up until the end of February 2013
›34,000 were MedsCheck/Diabetes MedsCheck delivered by 1300 pharmacies.
![Page 118: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/118.jpg)
PPI programs
Providing incentives to accredited pharmacies for the:
demonstrated delivery of agreed quality services to patients that are designed to improve their quality use of medicines demonstrated achievement of defined outcomes in
relation to the delivery of quality services to patients
![Page 119: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/119.jpg)
April 2013
Pharmacy Practice Incentive (PPI) Program
![Page 120: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/120.jpg)
Pharmacy Practice Incentive (PPI) Program
![Page 121: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/121.jpg)
Dose Administration Aids (DAAs)
To assist consumers in the community to better manage their medicines, with the objective of avoiding medication misadventure and associated
hospitalisation.
$132 million over the life of the Agreement (5
years)
Apr
Pharmacy Practice Incentive (PPI) Program
Australian Department of Health and Ageing Evaluation of the DAA/PMP Programs June 2010 – 4CPA http://www.health.gov.au/internet/main/publishing.nsf/Content/5B1B138DA00BB9C7CA2578150083984E/$File/DAA%20PMP%20Report.pdf
![Page 122: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/122.jpg)
Clinical Interventions
$97 million over the life of the Agreement (5 years)
Pharmacy Practice Incentive (PPI) Program
A clinical intervention: ‘any professional activity by the pharmacist directed towards improving the quality use of medicines and resulting in a recommendation for a change in the patient’s medication therapy, means of administration or medication-taking behavior.’
![Page 123: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/123.jpg)
Incentive Payments Eligible Community Pharmacies will be paid 4 times per year for meeting the PPI and QCPP requirements when delivering a DAA and a clinical intervention service.
Payments are calculated based on a complex formula for each claiming period that considers: the available funding pool for that period;
no. of pharmacies claiming for that period;
service volume (e.g., no. of DAA patients serviced in that period or clinical interventions delivered in that period ); and
claimable prescription volume for that period.
April 2013
![Page 124: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/124.jpg)
Staged Supply
April 2013
Pharmacy Practice Incentive (PPI) Program
$35 million over the life of the Agreement (5 years) An incentive payment of approx. $1000 annually
Supply medicines to consumers in periodic installments of less than the total required or prescribed quantity at agreed intervals.
Mental illness; Drug dependency; or Who are otherwise unable to manage their medicines safely
![Page 125: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/125.jpg)
Primary Health Care
April 2013
$75 million (Primary Health Care, Community Services Support and Working with Others) over the life of the Agreement (5 years)
Pharmacy Practice Incentive (PPI) Program
An incentive payment of approx. $850 will be paid annually
![Page 126: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/126.jpg)
Requirements
Elements Screening/Risk Assessment Service
Disease State Management Service
1. Diabetes 2. Respiratory Disease 3. Cardiovascular
Disease
4. Mental Health Conditions
5. Health Promotion Service
Eligible Community Pharmacies participating in this priority area must provide at least three services across more that one element in accordance with Program requirements.
April 2013
![Page 127: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/127.jpg)
April 2013
What does this mean? Eligible Community Pharmacies are required to have provided at least three services in accordance with the PPI Program Specific Guidelines (November 2012).
NOTE: Screening/Risk Assessment services and Disease State Management services can be delivered for the same disease state (element) and will be counted as two services
For example: 1. Health Promotion (e.g. Know your numbers, Show us your lungs, diabetes awareness etc.)
AND 2. Screening/Risk assessment service under
Cardiovascular disease AND
3. Disease State Management service under Cardiovascular disease
![Page 128: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/128.jpg)
1. Needle and syringe programs
2. Opioid Substitution programs
3. Return of Unwanted Medicines (RUM)
4. Staff training (Including Cert III & IV)
5. e-Health
6. NDSS Access Point
7. Pharmacy Delivery Service
8. Mental Health First Aid Training
April 2013
Community Services Support Eight elements focused on medicine safety, harm minimisation and services to support the community.
• Staff training requirements
• An incentive payment of approx. $850 will be paid annually
![Page 129: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/129.jpg)
Working with Others Service areas where inter-professional collaboration
might occur include: MedsCheck /Diabetes MedsCheck Dose Administration Aids Clinical Interventions Supplying Pharmacy Medicines and Pharmacy
Only medicines Disease State Management to improve Quality
use of Medicines (QUM) Home Medicine Review Medication Adherence Smoking Cessation Other professional Services including conditions
such as diabetes, respiratory disease, cardiovascular disease or mental health conditions.
April 2013
$850 annually for meeting PPI Program requirements when recording specific cases of inter-professional collaboration with at least three non-pharmacy health professional groups
![Page 130: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/130.jpg)
Concluding comments
› PHARMACY PRACTICE RESEARCH IS critical to development of the profession
› In the Australian context it has influenced government policy
› Challenges in translation - The infrastructure of pharmacy
- Slow rate of diffusion of practice change
- Pharmacists attitudes
- Resource limitations
- Resistance to boundary encroachment
- Underdeveloped relationships with other HCPs
![Page 131: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/131.jpg)
Concluding comments
Drivers for change - Need for new sources of income
- Shrinking income from dispensing -
- transparency in pricing from 'approved price to pharmacists' to 'approved ex-manufacturer price’
- recent report by Grattan Institute recommending a cap on the overall budget for the Pharmaceutical Benefits Scheme and drastically lower prices for generic drugs.
- Upsurge in discount pharmacies
- Aging of the population – rising needs for medication management services
![Page 132: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/132.jpg)
Acknowledgements
72
The Department of Health and Ageing for funding these projects through the Third and Fourth Community Pharmacy Agreements
![Page 133: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/133.jpg)
References
› Smith L et al. A Self-Management Model of Illness Behaviour Aids the Treatment of Asthma in an Australian Community Pharmacy Setting. Soc Sci & Med 2007;64:1501-11
› CL Armour et al. Pharmacists leading the way in diabetes care – disease state management JAPhA 2004, 44:455-466
› Krass I et al. Pharmacists leading the way in diabetes care – the impact on medication use and adherence JAPhA 2005; 45(1): 35-40
› I Krass, et al. The Pharmacy Diabetes Care Program: Evaluating the impact of a diabetes service model delivered by community pharmacists in Australia Diabetic Medicine 2007; 24:677-683
› Armour C et al. Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community, Thorax 2007 62: 496-502
› Adam Gordois, et al "Cost-effectiveness analysis of a pharmacy asthma care program in Australia Disease Management and Health Outcomes , 2007;15:387-96
› Krass I, et al. Diabetes Medication Assistance Service (DMAS) Stage 1: Impact and Sustainability of Glycaemic and Lipids Control in Patients with Type 2 Diabetes. Diab Med, 2011; 28: 987-93. doi: 10.1111/j.1464-5491.2011.03296.
› Saini B et al. Role of community pharmacists in asthma – Australian research highlighting pathways for future primary care models. Australasian Medical Journal. 2011;4:190-200.
› Saini B et al. Asthma disease management – Australian pharmacists’ interventions improve patients’ asthma knowledge and this is sustained. Patient Educ Couns 2011;83:295-302. [2 citations].
› Mitchell B, et al. Diabetes Medication Assistance Service: The Pharmacist's Role in Supporting Patient Self-Management of Type 2 Diabetes (T2DM) Patient Educ Couns 2011;83:288-94. [ 1 citation]
› Emmerton LM et al. Experiences of pharmacists involved in the delivery of a specialist asthma service in Australia. BMC Health Services Research (Impact factor 1.72, ERA rank B). 2012. doi: 10.1186/1472-6963-12-164.PMID:22709371
› Armour CL et al. Feasibility and effectiveness of an evidence-based asthma service in Australian community pharmacies: a pragmatic cluster randomised trial J Asthma. 2013; 50(3): 302-9.
› Smith LD et al The contribution of goal specificity to goal achievement in collaborative goal-setting for the management of asthma. Res Soc Admin Pharm doi:pii: S1551-7411(13)00019-3. 10.1016/j.sapharm.2013.02.002. [Epub ahead of print] PMID:23545118.
› Research and Development. Pharmacy Guild of Australia available at http://www.guild.org.au/The_Guild/tab-Pharmacy_Services_and_Programs/Research_and_Development/Research
![Page 134: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/134.jpg)
Please direct your questions regarding CEUs to Phil Emberley, Director of Pharmacy Innovation, CPhA, [email protected].
Continuing Education Form
CPhA National Conference 2013 June 1 – 4, 2013, Charlottetown, PE
The Canadian Council on Continuing Education in Pharmacy has approved CPhA as an Accredited Provider of continuing education. The conference has been accredited under program number 8002-2013-115-C-P for a total of 12.75 CEUs.
PLEASE NOTE: • Sessions indicated by an asterisk (*) are sponsored. These sessions are not accredited under the conference
program number. The sponsor will provide accreditation information at the session. • Pre-conference workshops are not accredited under the conference program number, nor listed on this
form. Participants will receive their Statement of Participation at the workshop(s).
Delegates are encouraged to use this form to track their learning. For delegates who must submit CEUs to their licensing body, please make a copy of this form for your files and submit the original to your provincial licensing body.
Name: __________________________________________________________________________________________
Province: _____________________________________ License #: ___________________________________
SUNDAY, JUNE 2, 2013
Time Session Speaker/Sponsor CEUs 7:00 am-8:30 am CE Satellite Breakfast Presentation* 1.0*
11:45 am-1:00 pm Luncheon Presentation – Learn How to Interpret Your Financials
Teva Canada 0.75*
1:15 pm-2:00 pm Balancing Risk & Benefits of Hormone Therapy for Menopause
Anne-Marie Whelan 0.75
1:15 pm-2:45 pm Pharmacy Practice Research – Oral Presentations Oral Abstract Presenters 1.5 1:15 pm-2:45 pm Canada’s Drug Review Processes Brian O’Rourke 1.5 2:00 pm-2:45 pm The Link Between the Heart and the Kidneys Marisa Battistella 0.75 3:00 pm-4:30 pm Pharmacy Practice Research – Oral Presentations Oral Abstract Presenters 1.5 3:00 pm-4:30 pm Improve Productivity in Community Pharmacy through
Workflow and Design Wayne Caverly 1.5
3:00 pm-4:30 pm Pharmacy Practice 3.0 – Putting Prescribing in Perspective
Matt Tachuk 1.5
Maximum daily CEUs under conference accreditation: 3.00 *Maximum daily CEUs from sponsored CE sessions: 1.75
![Page 135: CONFERENCE 2013 CONFERENCE 2013 CONFERENCE 2013 …€¦ · 2011 Dabigatran . VTE prophylaxis following THR/TKR . Health Canada Approvals of New Oral Anticoagulants . Rivaroxaban](https://reader034.vdocuments.mx/reader034/viewer/2022050420/5f8f5746ff703626e76a1b69/html5/thumbnails/135.jpg)
Please direct your questions regarding CEUs to Phil Emberley, Director of Pharmacy Innovation, CPhA, [email protected].
MONDAY, JUNE 3, 2013
Time Session Speaker/Sponsor CEUs 7:00 am-8:30 am CE Satellite Breakfast Presentation* Disease
Interrupted: Tobacco Reduction & Cessation Charl Els, Jane Ling LifeScan Canada
1.0*
8:30 am-9:30 am New Oral Anticoagulant Therapy: Is Newer Better? Bill Semchuk 1.0 8:30 am-9:30 am e-Health: A Cross Country Check-Up Justin Bates 1.0 8:30 am-9:30 am CPJ Session – Translating Research Evidence into
Australian Pharmacy Practice: Successes & Challenges Ines Krass 1.0
10:00 am-12:00 pm Pharmacy Practice Innovation Showcase Bareham, Barnes, Gray, Jorgenson, Sadowski, Taylor
2.0
2:30 pm-3:30 pm Looking Back, Looking Forward: The Public Policy Landscape in Pharmacy
Jeff Morrison 1.0
2:30 pm-4:30 pm Diabetes Mini Sessions (CANRISK, Diabetic Foot Care, 2013 CDA Guidelines)
Kerry Mansell, Rob Roscoe 2.0
3:30 pm-4:30 pm Debt Management for Pharmacy Students and New Practitioners
Michèle Seaton-Gascon 1.0
Maximum daily CEUs under conference accreditation: 5.00 *Maximum daily CEUs from sponsored CE sessions: 1.0 TUESDAY, JUNE 4, 2013
Time Session Speaker/Sponsor CEUs 7:00 am-8:30 am CE Satellite Breakfast Presentation* D-lemmas of
Vitamin D: Who Needs It and How Much? Stephanie Atkinson Kellogg Canada
1.0*
8:45 am- 9:45 am Managing Chronic Non-cancer Pain (CNCP): Finding Pearls & Avoiding Pitfalls
Loren Regier .75
8:45 am-10:15 am Pharmacy Practice Research – Oral Presentations Oral Abstract Presenters 1.5 8:45 am-10:15 am Connect and CARE: Engaging Patients Over-the-
Counter in Canada’s New Pharmacy Environment Lisa Guirguis, Sherrill Johnson
1.5
9:45 am-10:15 am Pharmacist’s Role in Shingles Vaccination Kathryn Slayter .75 10:30 am-11:15 am Parkinson’s Disease: Optimization of Medication
Management Janice Irvine-Meek .75
10:30 am-11:45 am Pharmacy Trends-A Time of Global Change Jeff Poston 1.25 11:15 am-11:45 am Managing Behavioural & Psychological Symptoms of
Dementia Susan Bowles .5
12:00 pm-1:30 pm Luncheon Presentation – from Pharmacist to Premier Hon. Darrell Pasloski (invited)
1.0
1:45 pm-2:45 pm The Multi-Generational Workplace David Foot 1.0 Maximum daily CEUs under conference accreditation: 4.75 *Maximum daily CEUs from sponsored CE sessions: 1.0